Walleye Capital
ENFN

Walleye Capital’s Enfusion, Inc. ENFN Stock Holding History

Walleye Capital’s Portfolio ENFN Stock Details ENFN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-33,062
Closed -$341K – 5326
2024
Q4 		$341K Buy
+33,062
New +$320K ﹤0.01% 3318

Other funds holding ENFN

FMC
FTV Management Company San Francisco, California $541M AUM 34.37% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
LECM
Lead Edge Capital Management New York $408M AUM 4.05% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Walleye Capital's ENFN Position: Q1 2025 in Review

Walleye Capital sold out of Enfusion, Inc. (ENFN) in Q1 2025, closing a stake of 33,062 shares — an estimated $341K sold.

Walleye Capital first reported a position in ENFN in Q4 2024 and held it in 1 quarter. The position peaked at $341K in Q4 2024. 132 funds tracked by Wall St. Rank hold ENFN as of Q1 2025.

  • Walleye Capital reported no remaining Enfusion, Inc. position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 33,062 Enfusion, Inc. shares in Q1 2025, an estimated $341K.
  • Walleye Capital first reported a position in Enfusion, Inc. in Q4 2024 and held it in 1 quarter.
  • Walleye Capital's Enfusion, Inc. position peaked at $341K in Q4 2024.
  • 132 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.